Neuroone Medical Technologies (NMTC) Q3 2024 earnings summary

Executive summary

• Achieved significant progress in commercialization, product development, and financial objectives in Q3 FY2024, including the limited commercial launch of the OneRF Ablation System and FDA clearance for three devices.

• Strong customer and strategic partner interest in the OneRF system and pipeline products, with a non-binding term sheet signed for global distribution.

• Accumulated deficit reached $71.7 million as of June 30, 2024, with ongoing net losses and a need for additional funding to sustain operations.

• Received a Nasdaq notice for non-compliance with minimum bid price requirements, with a compliance deadline of January 7, 2025.

• Progressed SEEG-based drug delivery and spinal cord stimulation programs, including successful animal studies and patent filings.

Financial highlights

• Q3 FY2024 product revenue was $826,000, up 31% from $630,000 in Q3 FY2023; nine-month product revenue reached $3.2 million, up from $1.2 million.

• Gross margin for Q3 FY2024 was $282,000 (34.1%), down from 38.7% in Q3 FY2023; nine-month gross margin was $0.9 million (29.5%), up from 21.7%.

• No collaboration revenue in 2024; prior year nine-month collaboration revenue was $1.46 million.

• Net loss for Q3 FY2024 was $2.8 million, improved from $3.5 million in Q3 FY2023; nine-month net loss was $9.0 million, compared to $8.7 million in the same period FY2023.

• Cash and cash equivalents as of June 30, 2024, were $1.6 million, down from $5.3 million as of September 30, 2023.

Outlook and guidance

• Plans to expand the OneRF limited commercial launch, complete product development for a new ablation indication, and target the next FDA application for early 2025.

• Management expects continued operating losses and significant expenses until higher commercial sales are achieved; additional funding is required to support operations beyond July 2025.

• Actively seeking a distribution partner for the OneRF system and monitoring Nasdaq compliance.

• Will exhibit and present at major neurosurgery conferences in September 2024.

• Initiating discussions to license or sell the spinal cord stimulation paddle lead product.